For permission requests, please contact NEJM Reprints at [email protected] Select the format you want to export the citation of this publication.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

He agreed that the 1-year improvement is small, but "it is important to understand that treatment with low-dose atropine will ...

SYD-101 contains a low dose of atropine sulfate, an antimuscarinic agent, in an ophthalmic solution. The NDA is supported by data from the phase 3 STAR trial (ClinicalTrials.gov Identifier: ...